Each material 8-K filed by a company listed on a US stock exchange (NYSE, Nasdaq, Cboe), read and summarized: what happened, the key numbers, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). This page lists the last 45 days; every brief stays on its company's 8-K page (4787 companies, A–Z).
Cognition Therapeutics received a Nasdaq deficiency letter on November 3, 2026, because its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days. The company has until May 3, 2027, to regain compliance, and the letter has no immediate effect on its listing. Third-quarter results showed a smaller net loss than a year earlier, but the company reported $31.5 million in cash as of September 30, 2026.
Nasdaq letter dated November 3, 2026 cites a closing bid price below $1.00 for 30 consecutive business days; compliance deadline is May 3, 2027
Q3 2026 net loss was $4.1 million, or $(0.04) per share, versus $4.9 million, or $(0.06) per share, in Q3 2025
Research and development expenses rose to $5.1 million from $3.8 million, while general and administrative expenses fell to $2.3 million from $2.6 million
Cash and restricted cash equivalents were $31.5 million at September 30, 2026; the company estimates funding into the fourth quarter of 2027
3M agreed on November 3, 2026 to a settlement intended to resolve most PFAS-related personal injury claims in the AFFF multidistrict litigation. The company will contribute a nominal $7.35 billion from 2026 through 2034, with a present value of $5.8 billion, and will record that amount as a pre-tax charge in the fourth quarter of 2026. The company says the charge does not change its previously issued 2026 guidance, and payments depend on claimant participation thresholds.
Nominal commitment of $7.35 billion over 2026 to 2034; present value of $5.8 billion
Pre-tax charge of $5.8 billion in Q4 2026, treated as a special item in adjusted results; 3M says 2026 guidance is unchanged
$50 million payment due in 2026 and no payments in 2027; payments subject to claimant participation thresholds
Settlement covers about 99% of current personal injury claims, involving roughly 115,000 to 120,000 eligible plaintiffs; 3M does not admit liability
Nasdaq's Hearings Panel granted CID HoldCo (Nasdaq: DAIC) continued listing, notified the company on October 28, 2026, but requires an application to transfer the listing to The Nasdaq Capital Market by November 2, 2026. The filing also reports that the Envoy Technologies acquisition closed on October 9, 2026, and that BladeRanger's designee, Avi Cohen, joined the board on October 23, 2026, so shareholders face a conditional listing outcome alongside a completed acquisition.
Nasdaq Hearings Panel granted continued listing, subject to submitting a transfer application to The Nasdaq Capital Market on or before November 2, 2026
Company closed the acquisition of 100% of Envoy Technologies' capital stock on October 9, 2026, paid in common stock and newly authorized Series C Convertible Non-Redeemable Preferred Stock
Avi Cohen appointed to the board on October 23, 2026, to Class I, serving until the 2029 Annual Meeting; filing states he is independent
Company filed its delinquent Form 10-Q for the quarter ended June 30, 2026, and issued a press release on October 29, 2026
Nasdaq's Hearings Panel granted Rain Enhancement Technologies' request for continued listing, subject to conditions tied to its proposed business combination with Tensor Networks and related financing. The combined company must meet all initial listing criteria by February 16, 2027, so the decision keeps the stock listed for now but depends on meeting those milestones.
Nasdaq Hearings Panel granted continued listing, subject to conditions
Conditions include milestones tied to the proposed Tensor Networks business combination and related financing
Combined company must comply with all initial listing criteria by no later than February 16, 2027
Class A common stock and warrants continue to trade on The Nasdaq Capital Market as RAIN and RAINW
Cumberland Pharmaceuticals plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, seeking Traditional Approval based on its FIGHT DMD trial and natural history data. The FDA raised concerns that the proposed data package may not be sufficient to show substantial evidence of efficacy and requested additional analysis, and the company states there is no assurance the FDA will accept the filing or approve the drug.
The 12-month Phase 2 FIGHT DMD trial showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus a control group.
The FDA suggested a Phase 3, randomized, placebo-controlled trial earlier in the review process, and expressed concerns about the sufficiency of the proposed data package at a pre-NDA meeting held this fall.
The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application.
The planned submission includes safety data from more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
Azio AI Holdings told the SEC it believes it has regained compliance with Nasdaq's $2,500,000 minimum stockholders' equity requirement. The company cites a third-quarter 2026 business combination with Azio AI Corporation, warrant exercises, and stock issued under an equity purchase agreement, and it notes Nasdaq will keep monitoring compliance and may delist the stock if compliance is not shown at the next periodic report.
Nasdaq notified the company on April 29, 2026 that stockholders' equity was below the $2,500,000 minimum, based on its Form 10-K for 2025.
Nasdaq extended the deadline; the company had to file a public report demonstrating compliance on or before October 26, 2026.
In the third quarter of 2026 the company issued 2,460,351 common shares and 973,450 Series A Preferred shares in the Azio AI Corporation business combination, plus warrant exercises for 450,000 common shares and about 920,000 common shares
The company says actual results for the quarter ended September 30, 2026 may differ materially from preliminary unaudited figures.
Citius Oncology received a Nasdaq notice on October 19, 2026 granting it until April 19, 2027 to evidence compliance with the $1.00 per share minimum bid price rule for continued Nasdaq Capital Market listing. The company's stock will keep trading under the symbol CTOR for now, but if it does not regain compliance by that date, Nasdaq will notify it that the stock is subject to delisting, and the company may appeal to a hearings panel.
Nasdaq extension runs through April 19, 2027 for compliance with the $1.00 per share bid price requirement.
Compliance requires a closing bid price of $1.00 or more for at least ten consecutive business days before April 19, 2027.
The company says it is evaluating options for regaining compliance and cannot assure it will do so.
The extension has no immediate effect on the CTOR listing on The Nasdaq Capital Market.
Polar Power, Inc. reported that it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, based on a series of convertible note, preferred stock, warrant and equity line transactions. The company estimates pro forma stockholders' equity of approximately $2.9 million, but the figures are preliminary and unaudited, and Nasdaq will keep monitoring compliance, so the company may still face delisting if it does not show compliance at its next periodic report.
Nasdaq deficiency letter dated May 1, 2026 cited the $2,500,000 minimum stockholders' equity rule; extension granted June 29, 2026
Company estimates preliminary pro forma stockholders' equity of approximately $2.9 million as of the filing date
Nasdaq will monitor compliance; the company may be subject to delisting if it does not evidence compliance at its next periodic report
Compliance must be demonstrated in a public report on or before October 28, 2026
T3 Defense Inc. said it believes it has regained compliance with Nasdaq's $10 million minimum stockholders' equity requirement, after holders exercised about 96% of its outstanding warrants as of September 30, 2026. The company has asked Nasdaq to confirm the resolution, but Nasdaq has not done so, and the company may face delisting if its next periodic report does not show compliance.
Nasdaq notice dated August 20, 2026 cited the $10,000,000 minimum stockholders' equity requirement under Listing Rule 5450(b)(1)(A).
Warrant liability rose from about $24.5 million at December 31, 2025 to about $124.4 million at June 30, 2026, producing a stockholders' deficit of about $19.7 million at that date.
As of September 30, 2026, warrant holders had exercised about 96% of outstanding warrants; pro forma stockholders' equity was about $99.9 million.
Nasdaq has not confirmed compliance; the next test is the Form 10-Q for the quarter ending September 30, 2026.
Nasdaq told ARC Group Acquisition I Corp that its warrants were out of compliance because their aggregate market value was below $1 million, and granted an extension to regain compliance by February 23, 2027. If the company does not meet the terms by that date, Nasdaq will notify it that its securities will be delisted, and the company may appeal to a Listing Qualifications Panel. The company says it expects to complete its previously announced business combination before that deadline.
Warrants' aggregate market value fell below the $1 million Nasdaq minimum under Listing Rule 5452(b)(C)
Company submitted its plan to regain compliance on October 12, 2026
Nasdaq granted an extension to regain compliance until February 23, 2027
Company expects to complete its previously announced business combination before February 23, 2027
The FDA lifted the clinical hold on the Investigational New Drug application for Aardvark's ARD-101 for hyperphagia in Prader-Willi Syndrome, and Aardvark said clinical development may resume. Resumption still depends on further engagement with the FDA on the Phase 3 trial design, and the company describes the Phase 3 HERO trial and its open-label extension as terminated.
FDA lifted the clinical hold on the ARD-101 IND, following a hold placed in May 2026 on the HERO and OLE trials
Dosing in the HERO trial was voluntarily paused on February 27, 2026 after reversible ECG changes in a separate healthy-volunteer study
A recent ECG study observed no cardiac events at ARD-101 doses of 200 mg and 400 mg twice daily
Aardvark will host a webcast on October 23, 2026 at 8:00 a.m. ET to review exploratory Phase 3 HERO and OLE data
SenesTech received a Nasdaq letter on October 20, 2026, saying its stock has closed below $1.00 for 30 consecutive business days, so it no longer meets Nasdaq's minimum bid price requirement. The company has until April 19, 2027 to regain compliance, and the notice has no immediate effect on its listing, but the company says it cannot assure it will regain compliance. In the same release, the company reported preliminary third-quarter revenue of about $1.1 million, the highest in its history.
Nasdaq notice received October 20, 2026; stock closed below $1.00 for 30 consecutive business days
Compliance period ends April 19, 2027; regaining compliance requires a closing bid of $1.00 or more for at least 10 consecutive business days
Preliminary Q3 revenue of about $1.1 million, up 40% from Q2 and 55% from Q3 2025
Long-term holder Glenbrook Capital Management reports a 38% ownership position and has offered to work with the board and management
TruGolf said it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement. Nasdaq had flagged a shortfall based on stockholders' equity of $2,060,281 as of June 30, 2026, and the company credits the Polymath acquisition and a Series B preferred stock financing for the change. Nasdaq will keep monitoring compliance and may move to delist the stock if the company's next periodic report does not show compliance.
Nasdaq had cited stockholders' equity of $2,060,281 from the June 30, 2026 Form 10-Q, below the $2,500,000 minimum
Polymath Research acquisition, completed in October 2026, added Polymath's net assets to the balance sheet
Series B preferred financing: $2,950,000 aggregate exercise price for 3,278 shares, plus 3,000 additional Series B warrants
Nasdaq will monitor compliance and may delist if the next periodic report does not show compliance
Alaunos Therapeutics said it believes it has regained compliance with Nasdaq's $2.5 million stockholders' equity requirement, following the October 14, 2026 closing of a financing with aggregate gross proceeds of approximately $350.0 million. Nasdaq has not yet confirmed the company's determination, and a Nasdaq Hearings Panel hearing remains scheduled for November 10, 2026. The company's status could still be challenged if it does not evidence compliance when it files its 2026 annual report.
Nasdaq's April 9, 2026 deficiency letter cited stockholders' equity of $2,153,000 in the 2025 Form 10-K, below the $2,500,000 minimum.
The financing closed October 14, 2026, with approximately $350.0 million in gross proceeds before placement agent fees and other expenses.
A Fairmount Fund II waiver covers 6,268 Series C Preferred shares, valued at approximately $9.0 million, that would otherwise carry a cash settlement right.
The Panel hearing is set for November 10, 2026; the company expects it to be cancelled once Nasdaq confirms compliance, and Nasdaq will keep monitoring the requirement.
Valor Energy said it regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement after raising its authorized common stock from 50 million to 500 million shares and reclassifying $41.90 million of warrants from liabilities to equity. The company also issued 4,510,000 warrants to investors on October 19, 2026. Nasdaq will keep monitoring, and the company may be delisted if it does not show compliance in its Form 10-Q for the period ended September 30, 2026.
Nasdaq notified the company on August 21, 2026 that its stockholders' deficit of $35,344,336 at June 30, 2026 did not meet the $2.5 million minimum
Authorized common stock was increased from 50,000,000 to 500,000,000 shares, effective August 6, 2026, and the June 2026 warrants were reclassified to equity
The company submitted a compliance plan to Nasdaq on October 5, 2026 and believes it has regained compliance
Failure to evidence compliance in the Form 10-Q for the period ended September 30, 2026 could lead to delisting
Nasdaq's Listing Qualifications staff said on October 20, 2026 that Vivos Therapeutics now meets the $2.5 million minimum stockholders' equity requirement, based on the company's October 19, 2026 8-K. The company said the SOD transaction, which included issuing Series C Convertible Preferred Stock, drove the improvement, but Nasdaq said the company could still face delisting if it does not show compliance in its next periodic report, and the preferred stock is convertible into up to 80,000,000 common shares, which could dilute existing holders.
Nasdaq letter dated October 20, 2026 says Vivos complies with the $2.5 million stockholders' equity minimum under Listing Rule 5550(b)(1).
Series C Convertible Preferred Stock with an aggregate stated value of $12,000,000 was issued as part of the SOD Sciences transaction, and is expected to increase stockholders' equity by more than $10 million.
Preferred stock converts at $0.15 per share into up to 80,000,000 common shares, subject to a 19.99% exchange cap pending stockholder approval.
Nasdaq said the company may be delisted if it does not evidence compliance upon filing its next periodic report.
ZoomInfo signed a memorandum of understanding on October 16, 2026, setting terms for a proposed settlement of a securities class action filed on September 4, 2024. The settlement provides for a $44 million payment to the class, a portion of which is expected to be covered by remaining insurance funds, and requires approval by the Washington District Court. The settlement would not resolve related shareholder derivative lawsuits, a related opt-out action, or a separate class action filed on June 25, 2026.
$44 million payment to the putative class, with a portion expected to be covered by remaining insurance funds
Memorandum of understanding executed October 16, 2026; subject to preliminary and final approval by the Washington District Court
Settlement would not resolve shareholder derivative suits, an opt-out direct action, or the class action filed June 25, 2026
Mustang Bio said Nasdaq granted it an additional 180-calendar day period, until April 12, 2027, to regain compliance with the $1.00 minimum bid price rule after it missed the October 12, 2026 deadline. The company must close at or above $1.00 for at least 10 consecutive business days in that period, and it has said it may effect a reverse stock split if necessary. If it does not regain compliance, Nasdaq will issue a delisting notice, and the company says there is no assurance it will meet all continued listing requirements.
Nasdaq granted an additional 180-calendar day grace period, through April 12, 2027, letter dated October 13, 2026
Compliance requires a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, generally no more than 20
Company has stated it may effect a reverse stock split if necessary; failure to comply would lead to a delisting notice
Mannatech told investors it believes it has regained compliance with Nasdaq's $2.5 million minimum stockholders' equity requirement, after a deficiency notice dated April 20, 2026. The claim rests on a pro forma adjustment tied to a share purchase agreement and a tax ruling, and the auditor review and Nasdaq's own view are still pending, so the listing outcome remains uncertain for shareholders.
Stockholders' equity was $(5,223,000) per the 2025 Form 10-K and $(4,970,000) as of June 30, 2026, per the Q2 Form 10-Q, against a $2,500,000 requirement.
Mannatech's share purchase agreement gives it 100% direct ownership of Mannatech Swiss Holdings GmbH, which the company says qualifies distributions for a 5% withholding tax rate.
Nasdaq will keep monitoring; if the 10-K for the year ending December 31, 2026 does not show compliance, the company may face delisting, with a right to appeal to a Nasdaq Hearings Panel.
The Q3 2026 Form 10-Q is expected on or before November 16, 2026, and the pro forma adjustment will be reviewed by the independent auditor.
Netcapital regained compliance with the Nasdaq minimum bid price rule after its closing bid price was at or above $1.00 for 10 consecutive business days, from September 23 through October 6, 2026, and Nasdaq closed the matter. The company engaged Adeptus Partners, LLC to re-audit fiscal years 2022 through 2026 because its previously issued financial statements for fiscal 2022 through 2025 should no longer be relied upon, and it has not finished evaluating the corrections that may be required. The company remains out of compliance with Nasdaq Listing Rule 5250(c)(1) for not filing its late annual and quarterly reports, so listing risk on that matter continues until a plan is accepted.
Nasdaq closed the bid price deficiency after the closing bid price was at or above $1.00 for 10 consecutive business days, September 23 through October 6, 2026.
Still out of compliance with Rule 5250(c)(1) for not filing the Form 10-K for fiscal year ended April 30, 2026 or the Form 10-Q for quarter ended July 31, 2026; plan due October 23, 2026.
Adeptus Partners, LLC engaged, with the Audit Committee approving on October 8, 2026, succeeding Fruci & Associates II, PLLC, which resigned effective August 12, 2026.
Financial statements for fiscal years 2022 through 2025 should no longer be relied upon; the scope of any restatement has not been determined.
Liquidia and its subsidiary Liquidia Technologies signed a settlement agreement with United Therapeutics on October 13, 2026, resolving all pending litigation between the companies. Liquidia will keep marketing YUTREPIA for pulmonary arterial hypertension but must remove the PH-ILD indication from the label and stop promoting it for that use, and it must make payments totaling a stated net $380.7 million in 2026 and 2027.
Net payment to United Therapeutics of $175.0 million due within 30 business days, plus $145.4 million in two $72.7 million installments due January 31, 2027 and April 30, 2027
Separate settlements with Sandoz, Henderson and PBM total about $60.3 million; the PBM agreement is with a related party that is controlled by a director, and the board's disinterested members approved it
Lender consent for a letter of credit tied to the settlement raised the minimum cash covenant under the revenue interest financing agreement from $15.0 million to $45.0 million
Preliminary, unaudited third-quarter 2026 YUTREPIA net product sales were $222.7 million, and cash and cash equivalents were $396.1 million as of September 30, 2026
Nasdaq's Hearings Panel decided on October 7, 2026, that CN Healthy Food Tech Group is in compliance and may remain listed, subject to conditions. The panel found the company failed to give Nasdaq and investors accurate information about its China Securities Regulatory Commission application, though it said the omission did not relate to finances or business operations.
Panel decision dated October 7, 2026; company may remain listed on Nasdaq
Company must keep remedial measures for three years from the panel decision date
One-year Discretionary Panel Monitor: any listing standard failure leads to a Staff Delisting Determination without a cure period
Company does not intend to seek Listing Council review; the council may still review on its own within 45 days
Benitec Biopharma said the FDA asked for additional available data, including from the company-sponsored OPMD Natural History Study, as discussions on an open-label, single-arm pivotal study for BB-301 continue. The company said it expects to confirm the final pivotal design in the first quarter of 2027 and that the pivotal study timeline remains on track, with patient enrollment planned to begin in mid-2027.
FDA requested additional available data, including from the Benitec-sponsored OPMD Natural History Study
Final pivotal study design expected to be confirmed in 1Q 2027
Patient enrollment for the BB-301 pivotal study planned to begin in mid-2027
Interim BB-301 Phase 1b/2a results to be presented as a late-breaking poster at ESGCT in Hamburg, October 27-30, 2026
A federal court in California ruled on September 29, 2026, on motions to dismiss in the lawsuit Joby Aero brought against Archer and an employee. The court narrowed the claims, dismissing some trade-secret and contract claims, some with leave to amend, while letting other claims proceed. The court also dismissed Archer's counterclaims against Joby without leave to amend, which limits Archer's own claims in the case.
Ruling date: September 29, 2026, U.S. District Court for the Northern District of California, Case No. 5:25-cv-10703-SVK
Certain trade-secret and contract-related claims against Archer and its employee were dismissed, some with leave to amend
Archer's counterclaims against Joby Aero and Joby Aviation under the Lanham Act and California's Unfair Competition Law were dismissed without leave to amend
Nexalin Technology received Nasdaq confirmation on September 30, 2026 that it has regained compliance with the $1.00 minimum bid price requirement. The company still must show at least $2,500,000 in stockholders' equity by January 4, 2027, or its stock faces delisting from Nasdaq.
Nasdaq confirmed on September 30, 2026 that the bid price requirement of $1.00 per share is met
Remaining condition: stockholders' equity of at least $2,500,000 by January 4, 2027
The company says it intends to meet the equity requirement, but gives no assurance it will
All In FutureTech Alliance disclosed that counsel for stockholder Primo Vital Limited sent letters in May and September 2026 claiming that its prior beneficial ownership disclosures about director Jingsheng (Jason) Lu were inaccurate. The company says it takes no position on the dispute over 11,986,523 shares it reported as roughly 31.3% of its common stock, and that this report does not resolve who controlled those shares.
Primo Letters dated May 22, 2026 and September 2, 2026 claim Mr. Lu was removed as Primo's director on May 19, 2026 and lost authority on March 3, 2026, when Ourgame was placed into liquidation in the Cayman Islands.
The company's Form 10-K and Special Meeting Proxy Statement reported Primo as record holder of 11,986,523 shares, about 31.3% of common stock, with shared voting power held by Mr. Lu.
The company relied on a December 11, 2024 joint Schedule 13D/A and says it will evaluate further information and its disclosure obligations.
Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate (OLC) on September 29, 2026, with chemistry and manufacturing data from a new third-party drug product vendor. The company expects FDA acceptance within 30 days and a new PDUFA date six months from resubmission, following a June 2026 Complete Response Letter. The company also appointed Meredith S. Manning as an independent director effective October 1, 2026.
NDA resubmitted September 29, 2026, including CMC data from a new third-party drug product manufacturing vendor and 12 months of OLC drug product stability data.
Company anticipates FDA acceptance within 30 days; new PDUFA date expected six months from resubmission.
June 2026 CRL cited the same third-party manufacturing deficiencies as the June 2025 CRL; the original vendor's FDA inspection had not occurred as of September 29, 2026.
Meredith S. Manning appointed independent director effective October 1, 2026; cash, equivalents and marketable securities were $61.4 million as of June 30, 2026.
Aldeyra Therapeutics said it intends to submit a Formal Dispute Resolution Request to the FDA, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026. The appeal's outcome and timing remain uncertain, and the filing states that the FDRR submission and meeting with the Office of New Drugs are expected in the fourth quarter of 2026.
Intends to submit an FDRR to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter for reproxalap
FDRR submission and a meeting with the Office of New Drugs are expected in the fourth quarter of 2026
Cash and cash equivalents were $45.1 million as of June 30, 2026; operational cash runway extended into 2029
After the market close on September 25, 2026, a jury awarded $5.7 billion in damages to the plaintiff in Taction Technology, Inc. v. Apple Inc., a case in which Burford has a financial entitlement. Burford says that if the verdict were paid as is, its entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds, but the amount is likely to change in post-trial and appellate proceedings. For shareholders, the verdict is not a final judgment or cash received, and Burford warns it could recover substantially less or incur a total loss.
Jury verdict of $5.7 billion in damages, announced in a release dated September 28, 2026, after the market close on Friday, September 25, 2026
If paid as is, Burford's entitlement would be $1.4 billion, split roughly equally between its balance sheet and its investment funds
Apple has filed a motion for judgment as a matter of law, and the Federal Circuit will scrutinize large verdicts on appeal
Burford states that it could recover substantially less than the verdict amount or, in certain circumstances, incur a total loss
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Frequently asked questions
Which filings get a brief?
Form 8-K filings by companies listed on a US stock exchange (NYSE, Nasdaq, Cboe; not over-the-counter stocks) that report a material event: results (Item 2.02), deals (1.01, 2.01), executive changes (5.02), restructuring (2.05), impairments (2.06), delisting notices (3.01), restatements (4.02), cybersecurity incidents (1.05), bankruptcy (1.03) and Regulation FD or other events (7.01, 8.01). Routine filings such as vote results or exhibits only are skipped.
How is the impact score set?
The AI rates each filing from 1 (routine) to 5 (major, such as a merger, bankruptcy or restatement) based only on what the filing says. It is a reading aid for sorting the day's filings, not a prediction of how the stock will move.
How quickly do briefs appear?
On weekdays the SEC filing feed is checked every 5 minutes from 6 am to 5:45 pm Eastern, when nearly all 8-Ks come in, and every hour after that until 10 pm. Briefs of the 1,000 largest companies follow within minutes; the others usually within the hour, or later the same day when many filings arrive at once.
Which companies are covered?
Every company with shares listed on the NYSE, Nasdaq or Cboe that files 8-Ks, about 4,500 of them. Foreign companies that report on Form 6-K instead are not included. The S&P 1500 only filter above narrows the list to the large, mid and small caps of the S&P Composite 1500.
Are older briefs kept?
Yes. This page shows the last 45 days, but every brief ever published stays online: each has its own page, and each company has an 8-K page listing all of its briefs, newest first, linked from its stock page and from the A-Z list of companies.